Overview Dividends

(ACHC) Acadia Healthcare - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00404A1097

Inpatient, Residential, Outpatient, Detox, Eating Disorder

Health Care Facilities
Market Cap in USD: 1,321m

IPO / Inception: 1994-03-04
Return 12m vs S&P 500: -66.8%

EPS (Earnings per Share)

EPS CAGR: 1.94%
EPS Trend: -25.3%

Last SUE: 0.90
Qual. Beats: 3

Revenue

Rev. CAGR: 10.11%
Rev. Trend: 95.7%

Last SUE: 0.35
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	67.3%
Value at Risk 5%th	93.3%
Relative Tail Risk	-15.77%

Reward TTM
Sharpe Ratio	-1.34
Alpha	-74.99
CAGR/Max DD	-0.52

Character TTM
Hurst Exponent	0.563
Beta	0.752
Beta Downside	1.131

Drawdowns 3y
Max DD	84.26%
Mean DD	35.31%
Median DD	20.54%

Description: ACHC Acadia Healthcare November 11, 2025

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) operates a network of behavioral-health facilities across the United States and Puerto Rico, including acute inpatient psychiatric hospitals, specialty residential programs (e.g., eating-disorder and recovery centers), comprehensive treatment centers, and outpatient clinics. Founded in 2005 and based in Franklin, Tennessee, the firm’s business model centers on delivering integrated mental-health services to meet community recovery needs.

Key operating metrics show FY 2023 revenue of roughly $1.2 billion with an adjusted EBITDA margin near 7 %, while average facility occupancy hovers around 85 %. Growth is being propelled by macro-level trends such as the rising prevalence of mental-health disorders (estimated to affect 1 in 5 U.S. adults) and expanding Medicaid/Medicare reimbursement rates for behavioral health services, which together create a favorable demand tailwind for providers like Acadia.

For a deeper dive into ACHC’s valuation metrics and peer comparison, you may find ValueRay’s analytical tools useful.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (107.4m TTM) > 0 and > 6% of Revenue (6% = 195.9m TTM)

FCFTA -0.05 (>2.0%) and ΔFCFTA 3.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.04% (prev 1.36%; Δ 5.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 334.9m > Net Income 107.4m (YES >=105%, WARN >=100%)

Net Debt (2.31b) to EBITDA (456.6m) ratio: 5.06 <= 3.0 (WARN <= 3.5)

Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (90.6m) change vs 12m ago -1.74% (target <= -2.0% for YES)

Gross Margin 81.42% (prev 42.34%; Δ 39.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.17% (prev 53.19%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.08 (EBITDA TTM 456.6m / Interest Expense TTM 131.0m) >= 6 (WARN >= 3)

Altman Z'' 0.88

(A) 0.04 = (Total Current Assets 748.0m - Total Current Liabilities 517.9m) / Total Assets 6.41b

(B) 0.06 = Retained Earnings (Balance) 411.7m / Total Assets 6.41b

(D) 0.13 = Book Value of Equity 412.6m / Total Liabilities 3.12b

Total Rating: 0.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.30

1. Piotroski 3.0pt

2. FCF Yield -9.57%

3. FCF Margin -10.63%

4. Debt/Equity 0.78

5. Debt/Ebitda 5.06

6. ROIC - WACC (= 0.93)%

7. RoE 3.49%

8. Rev. Trend 95.71%

9. EPS Trend -25.30%

What is the price of ACHC shares?

As of December 28, 2025, the stock is trading at USD 14.69 with a total of 1,807,802 shares traded.
Over the past week, the price has changed by +1.94%, over one month by -14.34%, over three months by -40.11% and over the past year by -61.41%.

Is ACHC a buy, sell or hold?

Acadia Healthcare has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy ACHC.

Strong Buy: 9
Buy: 1
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ACHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21.2	44.4%
Analysts Target Price	21.2	44.4%
ValueRay Target Price	11.7	-20.5%

ACHC Fundamental Data Overview December 27, 2025

Market Cap USD = 1.32b (1.32b USD * 1.0 USD.USD)
P/E Trailing = 12.3276
P/E Forward = 6.9541
P/S = 0.4044
P/B = 0.4145
P/EG = 1.32
Beta = 0.904
Revenue TTM = 3.27b USD
EBIT TTM = 272.5m USD
EBITDA TTM = 456.6m USD
Long Term Debt = 2.28b USD (from longTermDebt, last quarter)
Short Term Debt = 46.9m USD (from shortTermDebt, last quarter)
Debt = 2.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.31b USD (from netDebt column, last quarter)
Enterprise Value = 3.63b USD (1.32b + Debt 2.43b - CCE 118.7m)
Interest Coverage Ratio = 2.08 (Ebit TTM 272.5m / Interest Expense TTM 131.0m)
FCF Yield = -9.57% (FCF TTM -347.2m / Enterprise Value 3.63b)
FCF Margin = -10.63% (FCF TTM -347.2m / Revenue TTM 3.27b)
Net Margin = 3.29% (Net Income TTM 107.4m / Revenue TTM 3.27b)
Gross Margin = 81.42% ((Revenue TTM 3.27b - Cost of Revenue TTM 606.8m) / Revenue TTM)
Gross Margin QoQ = 96.43% (prev 96.72%)
Tobins Q-Ratio = 0.57 (Enterprise Value 3.63b / Total Assets 6.41b)
Interest Expense / Debt = 1.51% (Interest Expense 36.6m / Debt 2.43b)
Taxrate = 4.17% (1.67m / 40.0m)
NOPAT = 261.1m (EBIT 272.5m * (1 - 4.17%))
Current Ratio = 1.44 (Total Current Assets 748.0m / Total Current Liabilities 517.9m)
Debt / Equity = 0.78 (Debt 2.43b / totalStockholderEquity, last quarter 3.12b)
Debt / EBITDA = 5.06 (Net Debt 2.31b / EBITDA 456.6m)
Debt / FCF = -6.65 (negative FCF - burning cash) (Net Debt 2.31b / FCF TTM -347.2m)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.67% (Net Income 107.4m / Total Assets 6.41b)
RoE = 3.49% (Net Income TTM 107.4m / Total Stockholder Equity 3.08b)
RoCE = 5.08% (EBIT 272.5m / Capital Employed (Equity 3.08b + L.T.Debt 2.28b))
RoIC = 4.96% (NOPAT 261.1m / Invested Capital 5.26b)
WACC = 4.03% (E(1.32b)/V(3.75b) * Re(8.79%) + D(2.43b)/V(3.75b) * Rd(1.51%) * (1-Tc(0.04)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.70%
Fair Price DCF = unknown (Cash Flow -347.2m)
EPS Correlation: -25.30 | EPS CAGR: 1.94% | SUE: 0.90 | # QB: 3
Revenue Correlation: 95.71 | Revenue CAGR: 10.11% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.34 | Chg30d=-0.046 | Revisions Net=-5 | Analysts=10
EPS next Year (2026-12-31): EPS=1.97 | Chg30d=-0.257 | Revisions Net=-12 | Growth EPS=-5.3% | Growth Revenue=+4.5%

Additional Sources for ACHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle